2023.06-今，南京大学现代生物研究院，研究员，博导，至诚青年教授

2022.09-2023.02，美国北卡罗莱那大学教堂山分校,副研究员

2018.03-2022.09,美国北卡罗莱那大学教堂山分校,博士后

2016.10-2017.09，武汉枢密脑科学有限公司，研发总监

2022-05 Joseph S. Pagano Award, UNC-CH, USA 唯一获奖者

1. Wang J*, Yu X*, Gong W, Liu X, Park KS, Ma A, Tsai YH, Shen Y, Onikubo T, Pi WC, Allison DF, Liu J, Chen WY, Cai L, Roeder RG, Jin J#, Wang GG#. EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Nat Cell Biol. 2022 Mar;24(3):384-399. PMID: 35210568.

2. Liu X*, Wang J*, Gong W, Zhao S, Zhang C, Wu Q, Jain K, Boyer JA, Guo Y, Rodriguez J, Li M, Uryu H, Liao C, Hu L, Zhou J, Shi X, Tsai YH, Yan Q, Luo W, Zhang Q, Strahl BD, Kriegsheim A, Wang GG, Baldwin AS, Zhang Q#. A Role for Histone H3 Proline 16 Hydroxylation in Regulation of Mammalian Gene Expression. Nature Genetics. 2022 Nov;54(11):1721-1735. PMID: 36347944. (https://doi.org/10.1038/s41588-022-01212-x, News & Views).

3. Jun Wang*, Kwang-Su Park*, Xufen Yu, Weida Gong, H. Shelton Earp, Gang Greg Wang#, Jian Jin# and Ling Cai#. A cryptic transactivation domain of EZH2 binds AR and its splice variant promoting oncogene activation and prostate tumorigenesis. tumorous transformation. Nucleic Acids Research, 50(19), 10929-10946. PMID: 36300627.

4. Yu X*, Wang J*, Gong W, Ma A, Shen Y, Zhang C, Liu X, Cai L, Liu J, Wang GG#, Jin J#. Dissecting and Targeting Noncanonical Functions of EZH2 in Multiple Myeloma via an EZH2 Degrader. Oncogene. 2023 Mar;42(13):994-1009. doi: 10.1038/s41388-023-02618-5. PMID: 36747009.

5.  Wang J, Wang GG. No Easy Way Out for EZH2: Its Pleiotropic, Noncanonical Effects on Gene Regulation and Cellular Function. Int J Mol Sci. (2020) Dec 14; 21(24):9501. PMID: 33327550.

6.  Dardis GJ, Wang J, Simon JM, Wang GG, Baldwin AS. An EZH2-NF-κB regulatory axis drives expression of pro-oncogenic gene signatures in triple negative breast cancer. iScience. 2023 Jun 14;26(7):107115. doi: 10.1016/j.isci.2023.107115. PMID: 37416481.

7.  Yu X*, Li D*, Kottur J*, Shen Y, Kim HS, Park KS, Tsai YH, Gong W, Wang J, Suzuki K, Parker J, Herring L, Kaniskan HÜ, Cai L, Jain R, Liu J, Aggarwal AK, Wang GG#, Jin J#. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models. Science Translational Medicine. 2021 Sep 29;13(613):eabj1578. PMID: 34586829.

8. Pi WC, Wang J, Shimada M, Lin JW, Geng H, Lee YL, Lu R, Li D, Wang GG, Roeder RG#, Chen WY#. E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia. Blood. 2020 Jul 2;136(1):11-23. PMID: 32276273.

9. Xijuan Liu, Jeremy M. Simon, Haibiao Xie, Lianxin Hu, Jun Wang, Giada Zurlo, Cheng Fan, Travis S. Ptacek, Laura Herring, Xianming Tan, Mingjie Li, Albert S. Baldwin, William Y. Kim, Tao Wu, Marc W. Kirschner, Kan Gong, Qing Zhang. Genome-wide Screening Identifies SFMBT1 as a New Oncogenic Driver in Cancer with VHL Loss. Mol Cell, 2020 Mar 19: 77 (6): 1294-1306. PMID: 32023483.

10. Lu R, Wang J, Ren Z, Yin J, Wang Y, Cai L, Wang GG#. A model system for studying the DNMT3A hotspot mutation (DNMT3AR882) demonstrates a causal relationship between its dominant-negative effect and leukemogenesis. Cancer Res. 2019 Jul 15;79(14):3583-3594. PMID: 31164355.

11. Jing Zhang*, Tao Wu*, Jeremy Simon, Mamoru Takada, Ryoichi Saito, Cheng Fan, Xian-De Liu, Eric Jonasch, Ling Xie, Xian Chen, Xiaosai Yao, Bin Tean Teh, Patrick Tan, Xingnan Zheng, Mingjie Li, Cortney Lawrence, Jie Fan, Jiang Geng, Xijuan Liu, Lianxin Hu, Jun Wang, Chengheng Liao, Kai Hong, Giada Zurlo, Joel S. Parker, J. Todd Auman, Charles M. Perou, W. Kimryn Rathmell, William Y. Kim, Marc W. Kirschner, William G. Kaelin Jr., Albert S. Baldwin, Qing Zhang. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science, 2018 July 20; 361 (6399): 290-295. PMID: 30026228.

12. Cai L, Tsai YH, Wang P, Wang J, Li D, Fan H, Zhao Y, Bareja R, Lu R, Wilson EM, Sboner A, Whang YE, Zheng D, Parker JS, Earp HS#, Wang GG#. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell. 2018 Oct 18;72(2):341-354.e6. PMID: 30270106.